Developing therapies against different aging related diseases.
Juvenescence is a bio-pharma development company developing therapies focused on allowing people worldwide to live longer, healthier lives. We have raised USD $65M to build an ecosystem and pipeline of assets targeting ageing, age-related disease and regeneration.
Visit website: https://www.juvenescence.ltd/
Juvenescence is also referenced in the following:
Developing preventative medicines for age-related disease using ketone bodies
Focused on a novel target linked to one of the fundamental processes of aging
People at Juvenescence
CEO at Juvenescence and chairman of Portage Biotech, Inc.
Chief Executive Officer of the Epigenetics Division of Juvenescence Limited
Labiotech gathers feedback from European biotechs on Unity failure
Labiotech - 28-Aug-2020
General feeling that failures are bound to happen - but that their approaches can succeedRead more...
Juvenescence appoints a new CEO for its Epigenetic Division and Souvien Bio Ltd
Juvenescence - 11-Jun-2020
Goal is to develop drugs that target epigenetic mechanisms associated with neurodegenerationRead more...
Orion College ageing research receives 1 million UK pounds from Jim Mellon
Life Extension Advocacy Foundation (LEAF) - 18-May-2020
He believes in the importance of boosting immunoresilience among elderlyRead more...
Master Investor Magazine focuses on longevity in its Autumn edition
Master Investor - 01-Nov-2019
Interesting articles and some useful investment opportunitiesRead more...
A mission to change the lives of 1 billion people
Telegraph - 23-Sep-2019
Life extension technology will be expensive, so it'll create inequalities between poor, rich peopleRead more...
Today's 50 year-olds may live another 100 years
Forbes - 26-Aug-2019
Good summary of some major investments in life extension companiesRead more...